Baby Safety / Compounds / Enrofloxacin

Is Enrofloxacin safe for babies and kids?

Moderate risk for kids

Infants have immature drug-metabolizing enzymes (CYP450 ontogeny), reduced renal clearance, and different volume of distribution. Accidental exposure or breast milk transfer of Enrofloxacin poses heightened risk.

What is enrofloxacin?

The IUPAC name is 1-cyclopropyl-7-(4-ethylpiperazin-1-yl)-6-fluoro-4-oxoquinoline-3-carboxylic acid.

Also known as: 1-cyclopropyl-7-(4-ethylpiperazin-1-yl)-6-fluoro-4-oxoquinoline-3-carboxylic acid, Baytril, Enrofloxacine, Enrofloxacino.

IUPAC name
1-cyclopropyl-7-(4-ethylpiperazin-1-yl)-6-fluoro-4-oxoquinoline-3-carboxylic acid
CAS number
93106-60-6
Molecular formula
C19H22FN3O3
Molecular weight
359.4 g/mol
SMILES
CCN1CCN(CC1)C2=C(C=C3C(=C2)N(C=C(C3=O)C(=O)O)C4CC4)F
PubChem CID
71188

Risk for babies

Moderate risk

Infants have immature drug-metabolizing enzymes (CYP450 ontogeny), reduced renal clearance, and different volume of distribution. Accidental exposure or breast milk transfer of Enrofloxacin poses heightened risk.

Neonates and infants up to 12 months have incomplete blood-brain barrier development, immature Phase I/II metabolic enzymes (particularly CYP3A4, UGT1A1), and higher gastrointestinal permeability. Equivalent doses produce higher internal concentrations and longer residence times.

What to do: Minimize infant exposure through source control. For breastfeeding mothers: reduce maternal exposure. For formula-fed infants: use certified low-migration bottles and verified water sources. Consult pediatrician regarding any concerns.

Risk for pregnant and nursing people

Elevated risk

Enrofloxacin poses pregnancy risk through potential teratogenicity, altered pharmacokinetics (increased blood volume, changed CYP activity), and placental transfer. FDA pregnancy category should be evaluated.

Suspected reproductive toxicant (GHS H361) or suspected endocrine disruptor. Precautionary approach warranted. Animal studies or limited human data suggest developmental toxicity potential.

What to do: Minimize exposure during pregnancy and lactation. Consult healthcare provider regarding specific risks. Consider alternative products with lower hazard profiles.

Regulatory consensus

3 regulatory and scientific bodies have classified Enrofloxacin. The classifications differ — that's the data.

AgencyYearClassificationNotes
FDA—Veterinary-exclusive (not approved for human use)Enrofloxacin is not approved for human use in the United States
FDA2005Banned from poultry useBan implemented to protect efficacy of fluoroquinolones in treating human campylobacteriosis
IARC—Not classifiedIARC has not classified enrofloxacin

Regulators apply different standards of evidence — animal-data weighting, exposure-pattern assumptions, epidemiological power thresholds — which is why two scientific bodies can review the same data and reach different conclusions. The disagreement is the data.

Where kids encounter enrofloxacin

  • Industrial Facilities — Manufacturing plants, Chemical storage areas, Waste treatment sites
  • Occupational Environments — Factories, Warehouses, Transportation vehicles

Safer alternatives

Lower-risk approaches that achieve a similar outcome to Enrofloxacin:

  • Therapeutic alternatives (consult prescriber)
    Trade-offs: Drug-specific. Cannot substitute without medical guidance.
    Relative cost: 1.2-2×

Frequently asked questions

Is enrofloxacin safe for kids?

Infants have immature drug-metabolizing enzymes (CYP450 ontogeny), reduced renal clearance, and different volume of distribution. Accidental exposure or breast milk transfer of Enrofloxacin poses heightened risk.

What products contain enrofloxacin?

Enrofloxacin appears in: Manufacturing plants (Industrial facilities); Chemical storage areas (Industrial facilities); Factories (Occupational environments); Warehouses (Occupational environments).

What should I do if my child is exposed to enrofloxacin?

Minimize infant exposure through source control. For breastfeeding mothers: reduce maternal exposure. For formula-fed infants: use certified low-migration bottles and verified water sources. Consult pediatrician regarding any concerns.

Why do regulators disagree about enrofloxacin?

Enrofloxacin has been classified by 3 agencies including FDA, FDA, IARC, with differing conclusions. Regulators apply different standards of evidence (animal data weighting, exposure-pattern assumptions, epidemiological power thresholds), which is why two scientific bodies can review the same data and reach different conclusions. See the regulatory consensus table on this page for the full picture.

See Enrofloxacin in the baby app

Look up products containing enrofloxacin, compare to alternatives, and explore the full data record.

Open in baby View raw API data

Sources (2)
  1. US FDA/CVM: Enrofloxacin (Baytril) — 2004 Label Amendment for Feline Retinal Toxicity, Dose Restriction to 2.27 mg/kg in Cats, Canine Arthropathy Warning, Poultry Ban (2005), and Fluoroquinolone Resistance Public Health Considerations (2020) (2020) — regulatory
  2. ASPCA Animal Poison Control Center: Enrofloxacin and Fluoroquinolone Retinal Toxicity in Cats — Dose-Dependent Photoreceptor Degeneration, Clinical Presentation (Mydriasis, Blindness), and Irreversibility (2022) (2022) — veterinary

Reference data, not professional advice. Aggregates publicly available regulatory and scientific data; not a substitute for veterinary, medical, legal, or regulatory advice. Why we built ALETHEIA →